ARTICLE | Strategy
Building Bioverativ
How Biogen spinout Bioverativ plans to survive as stand-alone company
February 11, 2017 2:38 AM UTC
Biogen Inc.’s newly minted hematology spinout Bioverativ Inc. will have at least three years to build market share for its hemophilia therapies and flesh out its pipeline before gene therapies potentially hit the market. Given the level of competition, the newco has its work cut out for it, but CEO John Cox said it has the resources it needs.
Bioverativ launched Feb. 2 with a NASDAQ listing and Biogen’s hematology assets, which include two marketed long-acting clotting factor replacements and a portfolio of preclinical candidates. ...